| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | erlotinib (Tarceva®) |
| Formulation | film-coated tablet |
| Reference number | 908 |
| Indication | First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/09/2011 |
| NICE guidance | |